Lipid Nanoparticle mRNA Vaccines
Summary
USPTO published patent application US20260090989A1 by CureVac SE for lipid nanoparticle mRNA vaccine compositions. The application covers cationic lipids according to formulas (I)-(III), PEG lipids per formula (IV), and mRNA encoding antigens for influenza and rabies vaccination. The filing (Application No. 19409837) lists 14 inventors including Patrick Baumhof, Mariola Fotin-Mleczek, and Michael J. Hope.
What changed
CureVac SE filed patent application US20260090989A1 on December 5, 2025, covering lipid nanoparticle formulations with mRNA encoding antigenic peptides for medical uses. The claimed invention includes cationic lipids (formulas I-III), PEG lipids (formula IV), and mRNA sequences for vaccine applications targeting influenza and rabies. CPC classifications span A61K 9/1272, A61K 39/145 (influenza), and related therapeutic categories.
Patent applications do not impose compliance obligations on third parties. Parties reviewing this publication should note the application is pending and may claim priority from the December 5, 2025 filing date. No response or action is required from other entities. The application provides public notice of CureVac's claimed innovations in mRNA vaccine delivery technology using lipid nanoparticle carriers.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LIPID NANOPARTICLE mRNA VACCINES
Application US20260090989A1 Kind: A1 Apr 02, 2026
Assignee
CureVac SE
Inventors
Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHMIDT, Ying TAM
Abstract
The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
CPC Classifications
A61K 9/1272 A61K 9/19 A61K 31/16 A61K 31/23 A61K 31/40 A61K 31/7105 A61K 39/145 A61K 39/39 A61K 47/14 A61K 47/6929 A61P 31/16 A61P 37/02 A61K 2039/53 A61K 2039/55555 A61K 2039/70 B82Y 5/00 C12N 2760/16134
Filing Date
2025-12-05
Application No.
19409837
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.